Gastrointestinal Adverse Reactions In the pool of placebo-controlled trials, gastrointestinal adverse reactions occurred more frequently among patients who received RYBELSUS than placebo: RYBELSUS 14 mg once daily (41%), RYBELSUS 7 mg once daily (32%) and placebo (21%), including severe reactions (RYBELSUS 14 mg 2.0%, RYBELSUS 7 mg 0.6%, placebo 0.3%)
Its a companion programme designed to support people who already have a prescription from another provider, such as a GP, online pharmacy, or service like Second Nature
It is also FDA approved for moderate to severe obstructive sleep apnea in adults with obesity
Sustainable weight loss requires a balanced diet, regular physical activity, and a commitment to making long-term lifestyle changes
Standard protocols suggest a dose of 5 micrograms per kilogram of body weight to achieve therapeutic effects